CJC-1295 and ipamorelin are the canonical growth-hormone secretagogue pair. The pairing is older than most of the peptide conversations on the internet, and it remains one of the most carefully studied combinations in the research-interest data. This post explains why the pair is discussed together, what DAC versus no-DAC actually means, and why the timing of administration around sleep matters in the published designs.
Two complementary mechanisms
CJC-1295 is a growth-hormone releasing hormone analog. It binds the GHRH receptor and signals the pituitary to produce growth hormone. On its own, it raises the baseline of GH production.
Ipamorelin acts on the ghrelin receptor. It works on a different receptor and triggers pulsatile release of growth hormone. On its own, it sharpens the pulse but does not lift the baseline.
Together, the pair is discussed as raising the baseline and sharpening the pulse simultaneously. That is the entire reason the combination has its own name in the research-interest data.
DAC versus no-DAC
CJC-1295 comes in two common forms. The DAC version — drug-affinity complex — includes a chemical modification that extends the half-life from hours to roughly a week. The no-DAC version, often called modified GRF 1-29, has a half-life measured in minutes.
The choice between them is not cosmetic. DAC keeps the GHRH signal elevated continuously, which raises the baseline but flattens the natural pulsatility. No-DAC fires briefly and clears, which preserves the pulsatile pattern that the published designs care about most.
The discussion communities that focus on pulsatile signaling almost always prefer no-DAC for that reason. The discussion communities that focus on simpler dosing schedules tend to prefer DAC. There is no consensus answer — there is only the question of which endpoint you care about.
Why timing around sleep matters
The body's own growth hormone in healthy adults is released in pulses, with the largest pulse occurring in the first few hours of slow-wave sleep. The published designs that look at secretagogue administration consistently report that timing the dose to align with — rather than against — the natural sleep pulse changes the shape of the response.
In practice, the discussion conventions cluster around two timings. An evening dose shortly before sleep is the most common single-dose pattern in the research conversation. Researchers running multiple daily doses typically add a morning or post-workout dose, but the evening dose is the one that lines up with the body's own natural pulse.
Administering against the natural rhythm — for example, a single dose mid-morning with no evening dose — is not wrong, but the published response curves look different. If you are reading two studies and the timing differs, the timing is the variable to interrogate.
Practical handling notes
Both peptides are sensitive to repeated freeze-thaw cycles after reconstitution. Aliquot once if you can. Use bacteriostatic water for reconstitution if the study window is longer than a few days. Track lot numbers carefully — the published response curves are tighter than people expect, and a contaminated or partially degraded vial will widen your error bars before you have a chance to ask why.